See more : Akis Gayrimenkul Yatirim Ortakligi A.S. (AKSGY.IS) Income Statement Analysis – Financial Results
Complete financial analysis of Novartis AG (NVS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novartis AG, a leading company in the Drug Manufacturers – General industry within the Healthcare sector.
You may be interested
- TAKKT AG (TTK.DE) Income Statement Analysis – Financial Results
- Koninklijke KPN N.V. (KKPNF) Income Statement Analysis – Financial Results
- Archon Corporation (ARHN) Income Statement Analysis – Financial Results
- PT Geoprima Solusi Tbk (GPSO.JK) Income Statement Analysis – Financial Results
- EPL Limited (EPL.BO) Income Statement Analysis – Financial Results
Novartis AG (NVS)
About Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 46.66B | 51.83B | 52.88B | 49.90B | 48.68B | 53.17B | 50.14B | 49.44B | 50.39B | 53.63B | 58.83B | 57.56B | 59.38B | 51.56B | 45.10B | 42.58B | 38.95B | 36.75B | 32.53B | 28.25B | 24.86B | 23.15B | 19.34B | 21.83B | 20.42B | 23.04B |
| Cost of Revenue | 12.47B | 15.49B | 15.87B | 15.12B | 14.43B | 18.41B | 17.18B | 17.52B | 17.40B | 17.35B | 19.61B | 18.76B | 18.98B | 14.49B | 12.18B | 11.44B | 11.03B | 10.30B | 8.87B | 6.63B | 5.89B | 5.44B | 4.76B | 6.25B | 5.23B | 7.31B |
| Gross Profit | 34.19B | 36.34B | 37.01B | 34.78B | 34.25B | 34.76B | 32.96B | 31.92B | 32.98B | 36.29B | 39.22B | 38.81B | 40.39B | 37.07B | 32.92B | 31.15B | 27.92B | 26.45B | 23.66B | 21.62B | 18.97B | 17.71B | 14.58B | 15.59B | 15.19B | 15.73B |
| Gross Profit Ratio | 73.27% | 70.12% | 69.99% | 69.70% | 70.37% | 65.38% | 65.74% | 64.56% | 65.46% | 67.66% | 66.67% | 67.42% | 68.03% | 71.90% | 73.00% | 73.14% | 71.67% | 71.97% | 72.74% | 76.55% | 76.30% | 76.50% | 75.39% | 71.40% | 74.39% | 68.29% |
| Research & Development | 11.37B | 10.00B | 9.54B | 8.98B | 9.40B | 9.07B | 8.97B | 9.04B | 8.94B | 9.09B | 9.85B | 9.33B | 9.58B | 9.07B | 7.47B | 7.22B | 6.43B | 5.35B | 4.85B | 4.21B | 3.76B | 3.10B | 2.53B | 2.84B | 2.67B | 2.71B |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 16.47B | 2.14B | 2.19B | 2.48B | 2.62B | 3.06B | 2.94B | 2.97B | 2.48B | 2.28B | 2.25B | 2.13B | 1.96B | 1.74B | 1.54B | 0.00 | 8.98B | 7.66B | 7.94B | 6.95B | 1.29B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.86B | 12.00B | 11.77B | 12.38B | 14.55B | 14.35B | 15.08B | 13.32B | 12.05B | 11.85B | 11.13B | 10.45B | 9.80B | 8.87B | 9.33B | 0.00 | 0.00 | 0.00 | 0.00 | 6.39B |
| SG&A | 12.49B | 14.25B | 14.89B | 14.20B | 14.37B | 16.47B | 15.00B | 14.19B | 14.25B | 14.99B | 17.61B | 17.29B | 18.05B | 15.80B | 14.33B | 14.10B | 13.26B | 12.41B | 11.54B | 10.41B | 9.33B | 8.98B | 7.66B | 7.94B | 6.95B | 7.68B |
| Other Expenses | 559.00M | 2.90B | 895.00M | 1.45B | 1.40B | 1.05B | 362.00M | 417.00M | 824.00M | 1.12B | 852.00M | 672.00M | 1.76B | 680.00M | 1.14B | 867.00M | 1.45B | 741.00M | 363.00M | 463.00M | 0.00 | 0.00 | 0.00 | 0.00 | 949.00M | 0.00 |
| Operating Expenses | 24.42B | 27.15B | 25.32B | 24.63B | 25.17B | 26.59B | 24.33B | 23.65B | 24.01B | 25.20B | 28.31B | 27.29B | 29.39B | 25.55B | 22.94B | 22.18B | 21.13B | 18.50B | 16.75B | 15.08B | 13.08B | 12.08B | 10.18B | 10.78B | 10.57B | 10.39B |
| Cost & Expenses | 36.89B | 42.63B | 41.19B | 39.75B | 39.59B | 45.00B | 41.51B | 41.17B | 41.41B | 42.55B | 47.92B | 46.05B | 48.38B | 40.04B | 35.12B | 33.62B | 32.17B | 28.80B | 25.62B | 21.71B | 18.98B | 17.52B | 14.94B | 17.03B | 15.80B | 17.69B |
| Interest Income | 627.00M | 379.00M | 71.00M | 91.00M | 245.00M | 294.00M | 110.00M | 43.00M | 33.00M | 33.00M | 34.00M | 50.00M | 62.00M | 103.00M | 156.00M | 306.00M | 423.00M | 367.00M | 405.00M | 388.00M | 323.00M | 416.00M | 293.00M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 855.00M | 837.00M | 811.00M | 869.00M | 850.00M | 957.00M | 777.00M | 707.00M | 655.00M | 704.00M | 683.00M | 724.00M | 751.00M | 692.00M | 551.00M | 290.00M | 237.00M | 266.00M | 294.00M | 261.00M | 243.00M | 259.00M | 218.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 8.28B | 6.71B | 5.43B | 5.11B | 5.83B | 5.21B | 5.21B | 5.35B | 5.58B | 4.75B | 4.99B | 4.95B | 5.79B | 3.42B | 2.30B | 2.67B | 2.86B | 1.99B | 1.72B | 1.34B | 1.28B | 690.00M | 585.00M | 918.00M | 949.00M | 1.01B |
| EBITDA | 18.29B | 14.73B | 17.13B | 15.24B | 15.01B | 14.14B | 13.90B | 13.19B | 14.36B | 17.66B | 15.90B | 16.92B | 17.09B | 15.81B | 12.77B | 12.46B | 10.58B | 10.18B | 8.78B | 7.97B | 7.26B | 5.90B | 4.41B | 5.63B | 5.56B | 6.35B |
| EBITDA Ratio | 39.19% | 31.62% | 62.52% | 34.49% | 32.08% | 40.91% | 31.71% | 30.42% | 28.51% | 33.05% | 27.89% | 29.40% | 29.20% | 30.67% | 28.18% | 28.96% | 26.75% | 28.62% | 28.21% | 29.63% | 29.21% | 25.50% | 22.82% | 24.68% | 25.46% | 27.58% |
| Operating Income | 9.77B | 9.20B | 26.95B | 10.15B | 9.09B | 8.17B | 8.63B | 8.27B | 8.98B | 11.09B | 10.91B | 11.51B | 11.00B | 11.53B | 9.98B | 8.96B | 6.78B | 7.95B | 6.91B | 6.54B | 5.89B | 5.63B | 4.39B | 4.81B | 4.62B | 5.35B |
| Operating Income Ratio | 20.94% | 17.75% | 50.96% | 20.35% | 18.67% | 15.37% | 17.21% | 16.72% | 17.82% | 20.68% | 18.54% | 20.00% | 18.52% | 22.35% | 22.13% | 21.05% | 17.41% | 21.63% | 21.23% | 23.15% | 23.68% | 24.34% | 22.72% | 22.01% | 22.62% | 23.20% |
| Total Other Income/Expenses | -646.00M | 425.00M | -16.15B | -274.00M | -146.00M | -746.00M | -811.00M | -451.00M | -843.00M | 1.18B | -176.00M | -271.00M | -225.00M | 176.00M | -60.00M | 94.00M | 294.00M | -219.00M | 360.00M | -129.00M | -155.00M | 64.00M | 367.00M | 789.00M | 714.00M | 408.43M |
| Income Before Tax | 9.12B | 8.37B | 26.14B | 9.88B | 8.94B | 13.84B | 9.00B | 7.82B | 8.13B | 12.27B | 10.74B | 11.24B | 10.77B | 11.70B | 9.92B | 9.50B | 7.49B | 8.30B | 7.27B | 6.91B | 6.07B | 6.29B | 5.11B | 5.51B | 5.34B | 5.79B |
| Income Before Tax Ratio | 19.55% | 16.15% | 49.43% | 19.80% | 18.37% | 26.02% | 17.95% | 15.81% | 16.14% | 22.88% | 18.25% | 19.53% | 18.14% | 22.70% | 22.00% | 22.31% | 19.22% | 22.59% | 22.34% | 24.46% | 24.40% | 27.17% | 26.42% | 25.22% | 26.16% | 25.14% |
| Income Tax Expense | 551.00M | 1.42B | 2.12B | 1.81B | 1.79B | 1.22B | 1.30B | 1.12B | 1.11B | 1.55B | 1.44B | 1.63B | 1.53B | 1.73B | 1.47B | 1.34B | 947.00M | 1.28B | 1.12B | 1.13B | 1.01B | 1.07B | 869.00M | 1.11B | 1.15B | 1.37B |
| Net Income | 14.85B | 6.96B | 24.02B | 8.07B | 7.15B | 12.61B | 7.70B | 6.71B | 17.78B | 10.21B | 9.18B | 9.51B | 9.11B | 9.79B | 8.40B | 8.20B | 11.95B | 7.18B | 6.13B | 5.77B | 5.02B | 5.22B | 4.24B | 4.40B | 4.19B | 4.41B |
| Net Income Ratio | 31.83% | 13.42% | 45.43% | 16.18% | 14.68% | 23.72% | 15.36% | 13.58% | 35.29% | 19.04% | 15.60% | 16.51% | 15.35% | 18.99% | 18.62% | 19.24% | 30.67% | 19.52% | 18.85% | 20.42% | 20.17% | 22.56% | 21.92% | 20.13% | 20.51% | 19.13% |
| EPS | 7.15 | 3.19 | 10.71 | 3.54 | 3.12 | 5.44 | 3.28 | 2.82 | 7.40 | 4.21 | 3.76 | 3.93 | 3.75 | 4.28 | 3.70 | 3.62 | 5.15 | 3.06 | 2.63 | 2.28 | 1.99 | 1.88 | 1.49 | 1.70 | 0.62 | 0.33 |
| EPS Diluted | 7.10 | 3.17 | 10.63 | 3.52 | 3.08 | 5.38 | 3.25 | 2.80 | 7.29 | 4.13 | 3.70 | 3.89 | 3.70 | 4.26 | 3.69 | 3.59 | 5.13 | 3.04 | 2.62 | 2.27 | 1.97 | 1.84 | 1.49 | 1.70 | 0.62 | 0.33 |
| Weighted Avg Shares Out | 2.08B | 2.18B | 2.24B | 2.28B | 2.29B | 2.32B | 2.35B | 2.38B | 2.40B | 2.43B | 2.44B | 2.42B | 2.38B | 2.29B | 2.27B | 2.27B | 2.32B | 2.35B | 2.33B | 2.36B | 2.38B | 2.52B | 2.57B | 2.63B | 2.62B | 2.74B |
| Weighted Avg Shares Out (Dil) | 2.09B | 2.20B | 2.26B | 2.30B | 2.32B | 2.34B | 2.37B | 2.40B | 2.44B | 2.47B | 2.48B | 2.44B | 2.41B | 2.30B | 2.28B | 2.28B | 2.33B | 2.36B | 2.34B | 2.37B | 2.41B | 2.57B | 2.58B | 2.63B | 2.62B | 2.74B |
NVS or LLY: Which Is the Better Value Stock Right Now?
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Novartis (NVS) and Eli Lilly (LLY). But which of these two companies is the best option for those looking for undervalued stocks?
5 Low-Leverage Stocks to Buy Buoyed by Impressive Tech Earnings
The crux of safe investment lies in choosing a company that is not burdened with debt, as a debt-free stock is almost impossible to find. You can buy SAFRY, NVS, KEX, ACGL and LMB.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Novartis: Value Continues To Build With Double-Digit Percentage Growth Products
Kesimpta continues to do well as a self-administered drug for the treatment of patients with relapsing multiple sclerosis; Q2 2024 sales of $799 million, which is growth of 65% YOY. Pluvicto, as a treatment option for patients with metastatic castration-resistant...
Novartis: Best Performing Big Pharma Of Past 6 Months Still Looks A Solid Long-Term Bet
Novartis shares have risen over 20% in the past 6 months, making it the best-performing global pharmaceutical stock, with strong profitability and manageable debt. Despite some declining revenues from established brands, Novartis' pipeline and recent performance suggest continued growth, with...
Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI
SOMERVILLE, Mass.--(BUSINESS WIRE)--Generate:Biomedicines (“Generate”) today announced a multi-target collaboration with Novartis (NYSE: NVS) to discover and develop protein therapeutics across multiple disease areas. The collaboration leverages Generate's proprietary generative AI platform, “The Generate Platform,” to create potentially first- and best-in-class...
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
Novartis Wins FDA Approval of Kisqali for Early Breast Cancer
The FDA approves NVS' Kisqali to reduce the risk of disease recurrence in patients with HR+/HER2- early breast cancer.
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs. CEO Vas Narasimhan said the company was researching treatments that deal with the secondary effects of weight loss, but that...
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Vas Narasimhan, CEO of Novartis, says the pharmaceutical company does not plan to follow competitors in entering into the weight loss drugs market.
Source: https://incomestatements.info
Category: Stock Reports